Audience
Drug Discovery solution for pharma and biopharma companies
About Bruker Drug Discovery
Bringing a new drug into the market, from the first step to the final market introduction, is a time-consuming, highly regulated, and expensive process, which can take a decade or more. Final success crucially depends on the early availability of accurate analytical results, fast enough for taking the right decisions at the beginning of the development and minimizing late attrition rates. Today’s drug development is mainly based on a rational approach where typically establishing the biological target to focus on is the first key step. This target identification requires a deep understanding of the candidates´ properties to identify the most promising ones as quickly and reliable as possible. Once a biological target has been established, finding the most promising lead molecules is often seen as the next challenge. Typically, lead discovery is the identification of potential drug candidates – either small organic molecules or biologic assemblies with therapeutic potential.
Other Popular Alternatives & Related Software
Recursion
Recursion is a TechBio company focused on transforming drug discovery by combining biology, data, and artificial intelligence. Founded over a decade ago, the company pioneered the use of large-scale cellular imaging to train AI models that decode the biological drivers of disease. Recursion’s mission is to deliver better medicines through novel insights and precision design, reducing the high failure rates of traditional drug development. Its proprietary Recursion OS platform integrates massive biological datasets with machine learning to accelerate discovery from target identification to clinical development. The company has built an advanced pipeline of potential first-in-class and best-in-class therapies targeting aggressive cancers and rare diseases. Automated wet labs and robotics enable millions of experiments per week, feeding continuous learning into its AI models.
Learn more
BenevolentAI
BenevolentAI is an AI-enabled drug discovery platform and scientific technology company that unites advanced artificial intelligence, machine learning, and domain-specific science to accelerate the discovery, design, and development of new medicines for complex diseases by making sense of vast, diverse biomedical data and generating actionable scientific insights faster than traditional methods. Its proprietary Benevolent Platform ingests and harmonizes structured and unstructured biomedical information, including literature, genomics, clinical information, and multi-omics data, into a comprehensive knowledge graph, enabling scientists to reason across biological systems, generate hypotheses, predict novel drug targets, and design candidate molecules with higher confidence and lower failure rates.
Learn more
SYNTHIA Retrosynthesis Software
Expert-coded by chemists and engineered by computer scientists, SYNTHIA™ Retrosynthesis Software enables scientists to quickly find and easily navigate innovative and novel pathways for novel and published target molecules.
Quickly and efficiently scan hundreds of pathways to help you identify the best option according to your needs.
Explore the most cost-effective routes to your target molecules with state of the art visualization and filtering options.
Easily customize search parameters to eliminate or promote reactions, reagents or classes of molecules.
Explore unique and innovative syntheses that may be unknown for building your desired molecule.
Easily generate a list of commercially available starting materials for your synthesis.
Benefit from ISO/IEC 27001 Information Security Certification to guarantee the confidentiality, integrity, and protection of your data.
Learn more
Amazon Bio Discovery
Amazon Bio Discovery is an AI-powered application designed to accelerate early-stage drug discovery by combining computational biology models with real-world laboratory testing in a unified, “lab-in-the-loop” workflow. It provides scientists with direct access to a broad catalog of biological foundation models trained on large-scale biological datasets, enabling them to generate and evaluate potential drug candidates such as antibodies with greater speed and precision. Through an integrated AI agent, users can interact in natural language to select appropriate models, configure experiments, and optimize inputs without requiring advanced coding or infrastructure expertise. It allows researchers to build multi-step pipelines that combine different models, benchmark their performance, and reuse workflows across teams, improving collaboration between computational biologists and lab scientists.
Learn more
Integrations
No integrations listed.
Company Information
Bruker
Founded: 1960
United States
www.bruker.com/en/applications/pharma/drug-discovery.html
Videos and Screen Captures
Other Useful Business Software
AI-generated apps that pass security review
Retool lets you generate dashboards, admin panels, and workflows directly on your data. Type something like “Build me a revenue dashboard on my Stripe data” and get a working app with security, permissions, and compliance built in from day one. Whether on our cloud or self-hosted, create the internal software your team needs without compromising enterprise standards or control.
Product Details
Platforms Supported
Cloud
Training
Webinars
Videos
Support
Online
